As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Associations Standards of Medical Care in Diabetes (248, 249)
Joint and sleep problems
Common adverse reactions observed in adolescents include headache, abdominal pain, nausea, vomiting, and diarrhea, mirroring those reported in adult populations ( 10 , 11 )
The FDA's adverse event database documented more than 990 reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide as of May 31, 2026, per publicly available FDA safety communications
Mazidi, M., Karimi, E., Rezaie, P